Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28, 2026, management information circular ahead of its annual general and special meeting of shareholders scheduled for Nov. 10, 2026. The supplement corrects and restates the proposed special resolution authorizing a consolidation of the company’s Class A multiple voting shares and Class B subordinate voting shares. Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up.
The company also clarified that it will implement measures to cap the aggregate voting power of multiple voting shareholders at 70% if cancellations of Class B subordinate voting shares would otherwise cause that threshold to be exceeded. Previously submitted proxies will remain valid unless revoked or changed, and shareholders are encouraged to review the supplemental materials before the meeting.
To view the full press release, visit https://nnw.fm/HNKGe
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer